CN102058845B - 一种治疗黄斑变性的药物组合物 - Google Patents
一种治疗黄斑变性的药物组合物 Download PDFInfo
- Publication number
- CN102058845B CN102058845B CN2010105880315A CN201010588031A CN102058845B CN 102058845 B CN102058845 B CN 102058845B CN 2010105880315 A CN2010105880315 A CN 2010105880315A CN 201010588031 A CN201010588031 A CN 201010588031A CN 102058845 B CN102058845 B CN 102058845B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- pharmaceutical composition
- weight
- cnv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002780 macular degeneration Diseases 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 55
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims abstract description 54
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims abstract description 54
- 239000003814 drug Substances 0.000 claims abstract description 42
- 206010064930 age-related macular degeneration Diseases 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 230000008569 process Effects 0.000 claims abstract description 12
- 239000007924 injection Substances 0.000 claims abstract description 10
- 238000002347 injection Methods 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 6
- 239000006187 pill Substances 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 12
- 206010025421 Macule Diseases 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 230000007850 degeneration Effects 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 7
- 241000180649 Panax notoginseng Species 0.000 claims description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 231100000915 pathological change Toxicity 0.000 claims description 6
- 230000036285 pathological change Effects 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 241000407170 Curcuma Species 0.000 claims 3
- 235000014375 Curcuma Nutrition 0.000 claims 3
- 241000700159 Rattus Species 0.000 abstract description 20
- 230000004438 eyesight Effects 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004204 blood vessel Anatomy 0.000 abstract description 14
- 210000003161 choroid Anatomy 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 5
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 238000013534 fluorescein angiography Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 3
- 230000000877 morphologic effect Effects 0.000 abstract description 3
- 230000007170 pathology Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000935235 Fritillaria meleagris Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- -1 decoction Substances 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004377 improving vision Effects 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 229960002143 fluorescein Drugs 0.000 description 17
- 210000001525 retina Anatomy 0.000 description 17
- 239000003390 Chinese drug Substances 0.000 description 16
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 15
- 235000008216 herbs Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000012014 optical coherence tomography Methods 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 8
- 210000002189 macula lutea Anatomy 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 230000007547 defect Effects 0.000 description 7
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 7
- 208000006550 Mydriasis Diseases 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002601 radiography Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010063341 Metamorphopsia Diseases 0.000 description 3
- 206010073286 Pathologic myopia Diseases 0.000 description 3
- 206010039729 Scotoma Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 229910052743 krypton Inorganic materials 0.000 description 3
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 208000033379 Chorioretinopathy Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- VVVFZTHFVBQDJC-UHFFFAOYSA-N [Na].[As](=O)(O)(O)O.[K].[K] Chemical compound [Na].[As](=O)(O)(O)O.[K].[K] VVVFZTHFVBQDJC-UHFFFAOYSA-N 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000000630 fibrocyte Anatomy 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940020947 fluorescein sodium Drugs 0.000 description 2
- 210000004220 fundus oculi Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- 101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038491 Renal papillary necrosis Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 241000120020 Tela Species 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- IYPRWQPJYRBHIS-UHFFFAOYSA-N acetic acid;uranium Chemical compound [U].CC(O)=O IYPRWQPJYRBHIS-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105880315A CN102058845B (zh) | 2010-12-14 | 2010-12-14 | 一种治疗黄斑变性的药物组合物 |
PCT/CN2011/080758 WO2012079419A1 (zh) | 2010-12-14 | 2011-10-13 | 一种治疗黄斑变性的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105880315A CN102058845B (zh) | 2010-12-14 | 2010-12-14 | 一种治疗黄斑变性的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102058845A CN102058845A (zh) | 2011-05-18 |
CN102058845B true CN102058845B (zh) | 2011-11-16 |
Family
ID=43994470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105880315A Active CN102058845B (zh) | 2010-12-14 | 2010-12-14 | 一种治疗黄斑变性的药物组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102058845B (zh) |
WO (1) | WO2012079419A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102058845B (zh) * | 2010-12-14 | 2011-11-16 | 金明 | 一种治疗黄斑变性的药物组合物 |
CN104707102A (zh) * | 2015-02-27 | 2015-06-17 | 陈红 | 一种治疗湿性老年性黄斑变性的药物组合物 |
CN106924655B (zh) * | 2015-12-31 | 2021-05-04 | 天士力医药集团股份有限公司 | 一种治疗年龄相关性黄斑变性的中药组合物的制备方法 |
CN110613849A (zh) * | 2018-06-20 | 2019-12-27 | 珠海岐微生物科技有限公司 | 一种中药组合物及其在调节肠道微生物中的用途 |
EP3876712B1 (en) | 2018-11-14 | 2024-02-14 | Smilebiotek Zhuhai Limited | Screening methods for treatments of intraocular diseases or disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101474368A (zh) * | 2008-11-28 | 2009-07-08 | 安徽省药物研究所 | 一种治疗年龄相关性黄斑变性的中药及制备方法 |
CN101843780A (zh) * | 2010-05-21 | 2010-09-29 | 邹玲华 | 一种治疗黄斑变性的药物 |
CN102058845B (zh) * | 2010-12-14 | 2011-11-16 | 金明 | 一种治疗黄斑变性的药物组合物 |
-
2010
- 2010-12-14 CN CN2010105880315A patent/CN102058845B/zh active Active
-
2011
- 2011-10-13 WO PCT/CN2011/080758 patent/WO2012079419A1/zh active Application Filing
Non-Patent Citations (2)
Title |
---|
戴虹等.黄斑视网膜转位手术.《国外医学眼科学分册》.2000,第24卷(第5期),276-279. * |
金明.黄斑变性方药治疗脉络膜新生血管的临床疗效观察.《中国中西医结合杂志》.2009,第29卷(第6期),540-543. * |
Also Published As
Publication number | Publication date |
---|---|
CN102058845A (zh) | 2011-05-18 |
WO2012079419A1 (zh) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058845B (zh) | 一种治疗黄斑变性的药物组合物 | |
CN103845418B (zh) | 一种治疗眼底出血的中药组合物及其用途 | |
JP6663018B2 (ja) | 糖尿病性網膜症の治療のための漢方薬組成物 | |
CN102309575B (zh) | 一种药物组合物在制备防治糖尿病并发症药物中的应用 | |
CN104173503B (zh) | 一种中药颗粒剂的制备方法及其制备的中药颗粒剂和用途 | |
CN109512870B (zh) | 药物组合物及其制备方法和应用 | |
CN104161850B (zh) | 一种中药提取物的制备方法及其制备的中药提取物和用途 | |
CN102078509B (zh) | 一种治疗眼底出血的中药制剂及其制备方法 | |
CN102309632B (zh) | 一种药物组合物在制备防治糖尿病并发症药物中的应用 | |
CN114588236B (zh) | 组合物在制备药物中的用途 | |
CN108434166A (zh) | 一种血塞通药物组合物及其制备方法、制剂与应用 | |
CN102397399B (zh) | 一种中药组合物在制备防治糖尿病并发症药物中的应用 | |
CN112121104B (zh) | 一种缓解视疲劳及防治近视的中药组合物 | |
CN107982484A (zh) | 治疗糖尿病视网膜病变的中药复方提取物及其制备方法和应用 | |
CN106265622B (zh) | 益母草碱在制备视网膜视神经保护药物中的用途 | |
CN112294963B (zh) | 一种治疗年龄相关性黄斑变性的药物组合物 | |
CN107789430A (zh) | 一种中药组合物在制备预防/治疗黄斑变性疾病药物中的应用 | |
CN104161849B (zh) | 一种治疗糖尿病视网膜病变的中药片剂及其用途 | |
CN1222304C (zh) | 一种治疗玻璃体混浊的药物及其制备方法 | |
CN109820957A (zh) | 一种中药组合物在制备治疗眼底黄斑病变药物中的应用 | |
CN104173505B (zh) | 一种中药复方提取物的制备方法及其制备的中药复方提取物和用途 | |
CN104173504B (zh) | 一种治疗糖尿病视网膜病变的中药胶囊剂及其用途 | |
CN106389470A (zh) | 一种干细胞制剂及其制备方法和应用 | |
CN105833064A (zh) | 用于治疗糖尿病视网膜病变的明目汤剂 | |
CN105267632A (zh) | 一种治疗糖尿病性视网膜病变合并黄斑水肿的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER OWNER: JIN MING Effective date: 20130123 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100029 CHAOYANG, BEIJING TO: 300410 BEICHEN, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130123 Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 100029 China-Japan Friendship Hospital, Sakura East Road, Chaoyang District, Beijing, Hepingli Patentee before: Jin Ming |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee before: Tasly Pharmaceutical Group Co., Ltd. |